In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Prime Medicine Inc (NASDAQ: PRME) closed the day trading at $2.77 down -5.78% from the previous closing price of $2.94. In other words, the price has decreased by -$5.78 from its previous closing price. On the day, 0.82 million shares were traded. PRME stock price reached its highest trading level at $2.8701 during the session, while it also had its lowest trading level at $2.67.
Ratios:
For a better understanding of PRME, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.50 and its Current Ratio is at 6.50. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on December 10, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $10.
On May 20, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
Citigroup Upgraded its Neutral to Buy on May 16, 2024, while the target price for the stock was maintained at $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 15 ’24 when NELSEN ROBERT bought 3,200,000 shares for $6.25 per share. The transaction valued at 20,000,000 led to the insider holds 3,200,000 shares of the business.
ARCH Venture Partners XII, LLC bought 3,200,000 shares of PRME for $20,000,000 on Feb 15 ’24. The 10% Owner now owns 3,200,000 shares after completing the transaction at $6.25 per share. On Feb 15 ’24, another insider, ARCH Venture Partners X, LLC, who serves as the 10% Owner of the company, bought 3,200,000 shares for $6.25 each. As a result, the insider paid 20,000,000 and bolstered with 3,200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 385611712 and an Enterprise Value of 219160752. For the stock, the TTM Price-to-Sale (P/S) ratio is 454.14 while its Price-to-Book (P/B) ratio in mrq is 1.92. Its current Enterprise Value per Revenue stands at 273.951 whereas that against EBITDA is -1.058.
Stock Price History:
The Beta on a monthly basis for PRME is 1.79, which has changed by -0.5805991 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, PRME has reached a high of $9.77, while it has fallen to a 52-week low of $2.56. The 50-Day Moving Average of the stock is -16.26%, while the 200-Day Moving Average is calculated to be -40.97%.
Shares Statistics:
Over the past 3-months, PRME traded about 1.15M shares per day on average, while over the past 10 days, PRME traded about 1040750 shares per day. A total of 131.16M shares are outstanding, with a floating share count of 50.89M. Insiders hold about 61.20% of the company’s shares, while institutions hold 36.06% stake in the company. Shares short for PRME as of 1734048000 were 16129538 with a Short Ratio of 14.78, compared to 1731628800 on 15189710. Therefore, it implies a Short% of Shares Outstanding of 16129538 and a Short% of Float of 23.629998999999998.
